Positive Bioscience to offer Biodesix’s cancer tests in India

13 June 2017 (Last Updated June 13th, 2017 18:30)

India-based clinical genomics firm Positive Bioscience has signed an agreement to produce US-based Biodesix's GeneStrat and VeriStrat liquid biopsy tests in India. 

India-based clinical genomics firm Positive Bioscience has signed an agreement to produce US-based Biodesix's GeneStrat and VeriStrat liquid biopsy tests in India. 

The tests will be accessible for Indian patients with non-small cell lung cancer (NSCLC).

Testing will be carried out at Biodesix’s CLIA/CAP/CLEP/ISO certified laboratory located in Boulder, Colorado, US.

The predictive and prognostic blood-based proteomic VeriStrat test is designed to evaluate disease aggressiveness by identifying host response to the tumour.

According to the findings from clinical studies of the VeriStrat test, to allow treatment decisions, the classification as VeriStrat-Good or VeriStrat-Poor can be used for NSCLC patients with squamous or non-squamous histology, and those with wild-type or unknown EGFR mutation status.

Positive Bioscience CEO Samarth Jain said: “This partnership will provide lung cancer patients in India with access to critical liquid biopsy tests for the first time, enabling the highest standard of care.

"This partnership will provide lung cancer patients in India with access to critical liquid biopsy tests for the first time, enabling the highest standard of care."

“Through its industry-leading turnaround time, Biodesix’s tests will also accelerate time to treatment.”

The test is developed to inform the use of targeted therapies for lung cancer patients by measuring circulating tumour DNA and RNA using a sensitive droplet digital PCR platform.

The GeneStrat test delivers results for EGFR sensitising, EGFR resistance (T790M), KRAS and BRAF mutations, EML4-ALK, ROS1, and RETS fusion variants.

Biodesix CEO David Brunel said: “Our centralised testing approach enables rapid and high-quality test results within four days for Indian patients, well in advance of the 10-14 day average turnaround time for tissue-based testing.

In January, Biodesix also collaborated with Beijing-based Bioyong Industries and entered a distribution agreement with Israeli Progenetics in March.